Naveen Pemmaraju, MD of the MD Anderson Cancer Center, Houston, TX explains the results of a Phase II trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) (NCT02113982). Dr Pemmaraju briefly explains the history of BPDCN and how patients present. The trial is investigating a new targeted therapy aimed at hitting CD123/IL3 receptor alpha, which are believed to be overexpressed cells. He explains the importance of this trial as the first multicenter trial dedicated to patients with BPDCN. The results for both the frontline and refractory/relapsed settings are encouraging. Recorded at Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates